QOL-26. Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

Abstract BACKGROUND Patients with traditional high-grade glioma (grade 3-4) generally report worse health-related quality of life (HRQoL) compared to patients with low-grade glioma (grade 1-2). However, HRQoL changes over time across different molecularly defined tumor types, and associations between HRQoL and tumor types are unclear. METHODS We examined HRQoL data from the CODAGLIO 2.0 database, comprising patients with glioma from 16 randomized controlled trials. HRQoL was measured using the EORTC QLQ-C30 and QLQ-BN20 questionnaires. We analyzed differences in mean HRQoL at baseline and 3-month follow-up across tumor types (glioblastoma IDH-wildtype, astrocytoma IDH-mutant, and oligodendroglioma IDH-mutant/1p19q codeleted) and used linear mixed models (LMMs) to assess factors independently associated with HRQoL outcomes. RESULTS We included 4,301 patients with baseline HRQoL data, of which 3,215 (75%) had 3-month follow-up assessments. In stratified analyses, at 3 months, physical, role, and cognitive functioning were statistically and clinically significantly worse in glioblastoma compared to astrocytoma and oligodendroglioma. In LMMs, patients with astrocytoma showed worse physical functioning (-2.78, 95% CI: -4.68 to -1.01), cognitive functioning (-3.63, -6.18 to -1.05), pain (2.74, 0.41-4.95), communication deficits (5.03, 2.44-7.66), and seizures (4.49, 2.55-6.72), and oligodendroglioma patients showed worse social functioning (-5.39, -10.57 to -0.11), communication deficits (7.40, 1.63-12.81), and seizures (8.61, 4.17-14.26), compared to glioblastoma. None of these associations reached the threshold for clinical relevance. WHO performance status (PS) was the only variable in multivariable analysis with both statistically and clinically significant associations in 5/8 HRQoL scales. CONCLUSION Patients with glioblastoma show statistically clinically significantly worse physical and role functioning compared to IDH-mutant glioma. However, after adjusting for other variables in LMMs, patients with glioblastoma show statistically but not clinically significantly better HRQoL on several scales than patients with IDH-mutant glioma. WHO PS should be considered a critical factor in clinical decision-making, given its clinically meaningful association with most HRQoL scales.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-11-01
DOI
https://doi.org/10.1093/neuonc/noaf201.1527
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

QOL-26. Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

Paul M. Clément, Mirjam Renovanz, Ogechukwu A Asogwa, Johan A F Koekkoek et al.
Neuro-Oncology
Glioma Diagnosis and Treatment
article

QOL-26. Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

Paul M. Clément, Mirjam Renovanz, Ogechukwu A Asogwa, Johan A F Koekkoek, Caroline Hertler, Martin J. van den Bent, Kathy Oliver, Jaap C. Reijneveld, Michael Weller, Clemens Seidel, Linda Dirven, Matthijs van der Meulen, Claudia Panciroli, Thierry Gorlia, Roger Stupp, Christine Marosi, Martin Taphoorn, Emilie Le Guen, Lynn Lim, Annika Malmström, Florence Keime-Guibert, Brigitta G. Baumert, Wolfgang Wick, Francesca Martinelli, Alba A. Brandes, Neil K Aaronson, Ulrich Herllinger
article en

Abstract

Abstract BACKGROUND Patients with traditional high-grade glioma (grade 3-4) generally report worse health-related quality of life (HRQoL) compared to patients with low-grade glioma (grade 1-2). However, HRQoL changes over time across different molecularly defined tumor types, and associations between HRQoL and tumor types are unclear. METHODS We examined HRQoL data from the CODAGLIO 2.0 database, comprising patients with glioma from 16 randomized controlled trials. HRQoL was measured using the EORTC QLQ-C30 and QLQ-BN20 questionnaires. We analyzed differences in mean HRQoL at baseline and 3-month follow-up across tumor types (glioblastoma IDH-wildtype, astrocytoma IDH-mutant, and oligodendroglioma IDH-mutant/1p19q codeleted) and used linear mixed models (LMMs) to assess factors independently associated with HRQoL outcomes. RESULTS We included 4,301 patients with baseline HRQoL data, of which 3,215 (75%) had 3-month follow-up assessments. In stratified analyses, at 3 months, physical, role, and cognitive functioning were statistically and clinically significantly worse in glioblastoma compared to astrocytoma and oligodendroglioma. In LMMs, patients with astrocytoma showed worse physical functioning (-2.78, 95% CI: -4.68 to -1.01), cognitive functioning (-3.63, -6.18 to -1.05), pain (2.74, 0.41-4.95), communication deficits (5.03, 2.44-7.66), and seizures (4.49, 2.55-6.72), and oligodendroglioma patients showed worse social functioning (-5.39, -10.57 to -0.11), communication deficits (7.40, 1.63-12.81), and seizures (8.61, 4.17-14.26), compared to glioblastoma. None of these associations reached the threshold for clinical relevance. WHO performance status (PS) was the only variable in multivariable analysis with both statistically and clinically significant associations in 5/8 HRQoL scales. CONCLUSION Patients with glioblastoma show statistically clinically significantly worse physical and role functioning compared to IDH-mutant glioma. However, after adjusting for other variables in LMMs, patients with glioblastoma show statistically but not clinically significantly better HRQoL on several scales than patients with IDH-mutant glioma. WHO PS should be considered a critical factor in clinical decision-making, given its clinically meaningful association with most HRQoL scales.

Neuro-OncologyVol. 27(Supplement_5)
Linköping University (SE), University of Bonn (DE), German Cancer Research Center (DE), University of Zurich (CH), Heidelberg University (DE), University Hospital Bonn (DE), Dutch Cancer Society (NL), Leiden University Medical Center (NL), University Hospital Heidelberg (DE), Brain Tumour Charity (GB), University Hospital of Zurich (CH), Amsterdam Neuroscience (NL), National Center for Tumor Diseases (DE), Istituto delle Scienze Neurologiche di Bologna (IT), European Organisation for Research and Treatment of Cancer (BE), University Hospital Leipzig (DE), IRCCS Ospedale San Raffaele (IT), Bernstein Center for Computational Neuroscience Tübingen (DE), Hertie Institute for Clinical Brain Research (DE), Kantonsspital Graubünden (CH), Erasmus MC Cancer Institute (NL), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Medical University of Vienna (AT), Institut des Hautes Études Scientifiques (FR), University of Amsterdam (NL), Leipzig University (DE), KU Leuven (BE)
Openalex Percentile: Top 52%
Glioma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.